2021年欧洲风湿病学联盟协会/美国风湿病学会关于自身炎症性I型干扰素病诊断与管理考虑要点:CANDLE/PRAAS、SAVI和AGS
该考虑要点由欧洲风湿病学联盟协会/美国风湿病学会组建的多学科工作组制定,针对CANDLE/PRAAS、SAVI和AGS三种罕见自身炎症性I型干扰素病,基于系统文献综述、德尔菲问卷和共识方法,形成4条总体原则和17条考虑要点,以指导诊断评估、治疗和长期监测,旨在标准化并改善照护、生活质量和疾病结局。
要点
- 工作组制定4条总体原则和17条考虑要点,覆盖CANDLE/PRAAS、SAVI和AGS的诊断、治疗与长期监测。
- 考虑要点基于系统文献综述、德尔菲问卷和共识方法形成,代表当前最新知识。
- 目标为标准化并改善这些罕见自身炎症性I型干扰素病患者的照护、生活质量和疾病结局。
核心结论
- 这些考虑要点代表指导CANDLE/PRAAS、SAVI和AGS诊断评估、治疗与管理的最新知识,旨在标准化并改善照护、生活质量和疾病结局。
研究设计与样本
- 工作组由风湿病学家、神经病学家、免疫学家、遗传学家、患者权益代表和一名相关健康照护专业人员组成,针对系统文献综述制定研究问题。
- 基于文献、德尔菲问卷和共识方法制定指导患者管理的考虑要点。
主要发现
- 工作组制定4条总体原则和17条考虑要点,涉及CANDLE/PRAAS、SAVI和AGS的诊断、治疗和长期监测。
关键数值与推荐
- 共形成4条总体原则和17条考虑要点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoinflammatory type I interferonopathies, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), and Aicardi-Goutières syndrome (AGS) are rare and clinically complex immunodysregulatory diseases. With emerging knowledge of genetic causes and targeted treatments, a Task Force was charged with the development of "points to consider" to improve diagnosis, treatment, and long-term monitoring of patients with these rare diseases. METHODS: Members of a Task Force consisting of rheumatologists, neurologists, an immunologist, geneticists, patient advocates, and an allied health care professional formulated research questions for a systematic literature review. Then, based on literature, Delphi questionnaires, and consensus methodology, "points to consider" to guide patient management were developed. RESULTS: The Task Force devised consensus and evidence-based guidance of 4 overarching principles and 17 points to consider regarding the diagnosis, treatment, and long-term monitoring of patients with the autoinflammatory interferonopathies, CANDLE/PRAAS, SAVI, and AGS. CONCLUSION: These points to consider represent state-of-the-art knowledge to guide diagnostic evaluation, treatment, and management of patients with CANDLE/PRAAS, SAVI, and AGS and aim to standardize and improve care, quality of life, and disease outcomes.
引用
- Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS. Arthritis Rheumatol. 2022. PMID: 35315249. doi:10.1002/art.42087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。